SlideShare uma empresa Scribd logo
1 de 65
Dr Htet Htet
MBBS, MMedSc (Pharmacology)
Lecturer
Clinical Pharmacology
Thalidomide Tragedy
History
• Thalidomide - 1957 - in West Germany

• The German drug company “Grünenthal” developed and sold
the drug.

• Primarily prescribed as a sedative or hypnotic, to cure “anxiety,
insomnia, gastritis, and tension".
• Afterwards it was used against nausea and to alleviate morning
sickness in pregnant women.
• became an over the counter drug in Germany around

1960, and
• could be bought without a prescription.

• Shortly after the drug was sold, in Germany, between 5,000
and 7,000 infants were born with malformation of the
limbs (phocomelia). Only 40% of these children survived.
Time to Investigate
•

statistic - “50 % of the mothers with deformed children had taken thalidomide during
the first trimester of pregnancy.”

•

Throughout Europe, Australia, Canada and some part of America - cases were reported

of infants with phocomelia; only 50% of them survived.

•

Those subjected to thalidomide while in the womb experienced- limb deficiencies -

long limbs either were not developed or presented as stumps.
•

Other effects - deformed eyes, hearts, alimentary, and urinary tracts, and blindness and
deafness.

•

During that time period the use of medications during pregnancy was not strictly
controlled, and drugs were not thoroughly tested for potential harm to the fetus.
Time to withdrawn from market
• Thalidomide was withdrawn from the market
in 1961
• IT WAS A BIG LESSON FOR THE WHOLE
WORLD CONCERNING WITH DRUG SAFETY
AND REGULATION
- An adverse drug reaction (ADR) is an expression that

describes harm associated with the use of given
medications at a normal dosage during normal use.
- ADRs may occur following a single dose or prolonged
administration of a drug or result from the combination of

two or more drugs.
- The meaning of this expression differs from the meaning of
"side effect", as it might also imply that the effects can be
beneficial.
• Over 2 MILLION serious ADRs yearly

• 100,000 DEATHS yearly
• ADRs 4th leading cause of death ahead of pulmonary disease,
diabetes, AIDS, pneumonia, accidents and automobile deaths
• Ambulatory patients ADR rate—unknown
• Nursing home patients ADR rate— 350,000 yearly

Data from
Institute of Medicine, National Academy Press, 2000
Lazarou J et al. JAMA 1998;279(15):1200–1205
Gurwitz JH et al. Am J Med 2000;109(2):87–94
• Type A:
– Augmented pharmacologic effects - dose dependent and predictable

• Type B:
– Bizarre effects (or idiosyncratic) - dose independent and unpredictable

• Type C: Chronic effects (continuous)
• Type D: Delayed effects
• Type E: End-of-treatment effects
• Types A and B were proposed in the 1970s,and the other types were
proposed subsequently when the first two proved insufficient to classify
ADRs.
• 80% of ADR,
• usually a consequence of the drug’s primary pharmacological effect (e.g.
bleeding from warfarin)or
• a low therapeutic index (e.g. nausea from digoxin), and
• predictable

• dose-related, usually mild,
• But may be serious or even fatal (e.g. intracranial bleeding from warfarin).
• usually due to inappropriate dosage, especially when drug elimination is

impaired.
• The term ‘side effects’ is often applied to minor type A reactions.
• Bizarre effects (or idiosyncratic)
• dose independent and

• Unpredictable

(not

an

extension

pharmacological action of the drug)
For example:
• hepatotoxicity due to paracetamol
• tinnitus induced by aspirin
• ototoxicity with aminoglycosides

of

main
• Results from Chronic or continuous use
For example
• Analgesic nephropathy

• osteoporosis during continued high-dose
glucocorticoid therapy

• tardive dyskinesia during continuous use of
antipsychotic drugs
• Teratogenic
Thalidomide

- amelia or micromelia or phocomelia

phenytoin

-fetal hydantoin syndrome

tetracyclines

-teeth malformation and discoloration

aspirin

-early closure of ductus arteriosus

carbamazepine

-cleft lip and palate, microcephaly

wafarin

- saddle nose

sodium valproate - spina bifida
DES

- vaginal clear cell adenocarcinoma
• Rebound adrenal insufficiency

• Withdrawal syndrome (tachycardia on abrupt

discontinuation of β-adrenoceptor blockade)

• second malignancies following successful
chemotherapy.
a. Adverse effects related to the
pharmacological action of the drug

main

a. Adverse effects unrelated to the main
pharmacological action of the drug
• predictable,
• at least this action is well understood.
• They are sometimes referred to as type A
('augmented‘)
Examples:
• postural hypotension occurs with α1-adrenoceptor

antagonists,
• bleeding with anticoagulants,

• sedation with anxiolytics
• intracerebral bleeding caused by anticoagulants,

• hypoglycaemic coma from insulin
• drug dependence produced by opioid analgesics
Examples
• paracetamol hepatotoxicity
• aspirin-induced tinnitus
when susceptibility is increased
• eg. during pregnancy

Or if the patient has some predisposing conditions,
• glucose 6-phosphate dehydrogenase deficiency

• mutation in the mitochondrial DNA that predisposes to
aminoglycoside ototoxicity
Unpredictable idiosyncratic reactions
– drug-induced hepatic or renal necrosis,
– bone marrow suppression,

– carcinogenesis and
– disordered fetal development.

– aplastic anaemia from chloramphenicol
– anaphylaxis in response to penicillin

idiosyncratic reactions are termed type B ('bizarre')
in the Rawlins & Thomson (1985) classification.
• such reactions cannot be excluded by preapproval clinical

trials (which might typically expose only a few thousand
individuals to the drug), and
• the association may come only after years of use,
• so there is a need for continued monitoring by regulatory
authorities after drugs have been licensed and marketed.
• An

example

is

the

association

between

pulmonary

hypertension and valvular heart disease with fenfluramine,

an appetite suppressant that had been used for several years,
and also with dexfenfluramine.
Erythematous maculopapular eruption due to penicillin: rashes of this kind are by far the
most common reactions to drugs.

Vervloet D , and Durham S BMJ 1998;316:1511-1514

©1998 by British Medical Journal Publishing Group
Erythema multiforme due to sulphonamide treatment, showing characteristic target-like
lesions.

Vervloet D , and Durham S BMJ 1998;316:1511-1514

©1998 by British Medical Journal Publishing Group
Fixed drug eruption, so called because the lesion recurs at the same site after each
administration—in this case, due to barbiturates.

Vervloet D , and Durham S BMJ 1998;316:1511-1514

©1998 by British Medical Journal Publishing Group
Exfoliative dermatitis—a severe complication in this case due to co-trimoxazole.

Vervloet D , and Durham S BMJ 1998;316:1511-1514

©1998 by British Medical Journal Publishing Group
Eiferman et al.
Ciprofloxacin
microprecipitates and
macroprecipitates in the
human corneal
epithelium.
J Cataract Refract Surg
2001; 27(10): 1701-2
Brazier et al. Ecstasy
related periodontitis and
mucosal ulceration—a case
report. Br Dent J 2003;
194(4): 197-9
• toxicity testing in animals and humans are important for seeking

approval to market a new drug.

• Nevertheless, harmful effects are often encountered during
therapeutic use, often the result of misprescribing, but also due to
the emergence of toxic effects not detected in animals.

• These harms are usually referred to as 'adverse drug reactions'
(ADRs) and are of great concern to drug regulatory authorities,

• For establishing the safety as well as the efficacy of drugs.
1. Listen to your patient (Patients may tell you about

symptoms they have experienced since taking a
new medicine and it is important to listen to the

patient’s own concerns regarding their drug
therapy.)

2. Alert by yourself (some adverse reactions may not

be apparent to the patient, you will need to be
alert to the possible occurrence of ADRs.)
3. Trust your own observations and initiative
- vital in this respect, in linking a sign or
symptom to either current or previous
therapy. (Remember these can include overthe-counter (OTC) drugs and unlicensed
herbal remedies).
Other things to be alert for include:

• Abnormal clinical measurements
(e.g. temperature, pulse, blood pressure, blood

glucose, body weight) while on drug therapy

• Abnormal biochemical or haematological
laboratory results while on drug therapy. For

example, plasma drug concentrations or liver biopsy
where drug-induced hepatitis is suspected
• Introduced in 1964 after Thalidomide tragedy

• Spontaneous reporting system
• Early warning system
• Over 600,000 confidential reports received in UK
Who can report?
•
•
•
•
•
•
•
•
•

Doctors
Dentists
Pharmacists
Nurses
Midwives
Health visitors
Non medical prescribers
Now
Patients also ………..
Where to report?
• www.yellowcard.gov.uk (online completion)
• http://yellowcard.mhra.gov.uk/
• Or by calling to 0808 100 3352

• Yellow cards can be available in BNF books ..
When to report?
•
•
•
•
•

If you suspect ADR,
Do not assume someone else will be reported.
Only 2-4% of ADR are reported.
Only 10% of serious ADR are reported.
“No”
You don’t need to be completely certain that
what you have seen is ADR. ***
How to get latest informations for
yourself?
• don’t miss for updates for yourself also.
• DRUG SAFETY UPDATES!!
• Published monthly
• Register for updates ..
• http://www.mrha.gov.uk/publications/safetyg
uidance/DrugSafetyUpdate/index.htm
• Vigabactrin – visual field defects
• Cyproterone acetate – hepatotoxicity
• Alendronate – severe oesophageal toxicity
• sibutramine – (Meridia (sibutramine):
– Market Withdrawal Due to Risk of

Serious Cardiovascular Events) 2010-2011
“All health care professionals have a responsibility to
inform colleagues about clinically important drug

reactions that they detect, even if a well
recognized or causal link is uncertain”.

Edwards IR and Aroson JK. Adverse Drug Reactions:
Definitions, Diagnosis and Management. Lancet 2000; 356:
References
• http://en.wikipedia.org/wiki/Thalidomide
• http://www.who.int/bulletin/volumes/91/8/BLT12-111609-table-T1.html
• http://www.fda.gov/Drugs/DevelopmentApprova
lProcess/DevelopmentResources/DrugInteraction
sLabeling/ucm114848.htm
• http://www.mhra.gov.uk/Safetyinformation/How
wemonitorthesafetyofproducts/Medicines/TheYe
llowCardScheme/Informationforhealthcareprofes
sionals/Adversedrugreactions/index.htm
• http://www.docstoc.com/docs/57017777/TheYellow-Card-Scheme-Reporting
• British National Formularly (61st Edition)

Mais conteúdo relacionado

Mais procurados

Introduction to Adverse Drug Reactions
Introduction to Adverse Drug ReactionsIntroduction to Adverse Drug Reactions
Introduction to Adverse Drug Reactions
Abhik Seal
 

Mais procurados (20)

Adverse drug reaction monitoring
Adverse drug reaction monitoringAdverse drug reaction monitoring
Adverse drug reaction monitoring
 
Drugs Interactions.ppt
Drugs Interactions.pptDrugs Interactions.ppt
Drugs Interactions.ppt
 
Clinical pharmacy
Clinical pharmacyClinical pharmacy
Clinical pharmacy
 
Introduction to Adverse Drug Reactions
Introduction to Adverse Drug ReactionsIntroduction to Adverse Drug Reactions
Introduction to Adverse Drug Reactions
 
Therapeutic Index of drugs and Factors modifying drug action
Therapeutic Index of drugs and Factors modifying drug action Therapeutic Index of drugs and Factors modifying drug action
Therapeutic Index of drugs and Factors modifying drug action
 
Prescribing information & Package insert (Please Comment before download )
Prescribing information & Package insert   (Please Comment before download )Prescribing information & Package insert   (Please Comment before download )
Prescribing information & Package insert (Please Comment before download )
 
14ab1t0019 drug distribution
14ab1t0019   drug distribution14ab1t0019   drug distribution
14ab1t0019 drug distribution
 
RESEARCH IN HOSPITAL PHARMACY and PHARMACY EDUCATION
RESEARCH IN HOSPITAL PHARMACY and PHARMACY EDUCATIONRESEARCH IN HOSPITAL PHARMACY and PHARMACY EDUCATION
RESEARCH IN HOSPITAL PHARMACY and PHARMACY EDUCATION
 
Hospital pharmacy syllabus
Hospital pharmacy syllabusHospital pharmacy syllabus
Hospital pharmacy syllabus
 
Essential Drug Concept
Essential Drug ConceptEssential Drug Concept
Essential Drug Concept
 
Dispensing errors and Its Prevention
Dispensing errors and Its PreventionDispensing errors and Its Prevention
Dispensing errors and Its Prevention
 
Drug information and poison information
Drug information and poison informationDrug information and poison information
Drug information and poison information
 
Drug distribution sjk
Drug distribution  sjkDrug distribution  sjk
Drug distribution sjk
 
Case Studies Clinical pharmacy
Case Studies Clinical pharmacyCase Studies Clinical pharmacy
Case Studies Clinical pharmacy
 
Drugs used in pregnancy and lactation
Drugs used in pregnancy and lactationDrugs used in pregnancy and lactation
Drugs used in pregnancy and lactation
 
Adverse Drug Reactions
Adverse Drug ReactionsAdverse Drug Reactions
Adverse Drug Reactions
 
Hospital formulary
Hospital formularyHospital formulary
Hospital formulary
 
Adverse drug reaction ppt
Adverse drug reaction pptAdverse drug reaction ppt
Adverse drug reaction ppt
 
Pharmacy and Therapeutic committee
Pharmacy and Therapeutic committeePharmacy and Therapeutic committee
Pharmacy and Therapeutic committee
 
Barriers of patient counseling in a community pharmacy and Strategies to over...
Barriers of patient counseling in a community pharmacy and Strategies to over...Barriers of patient counseling in a community pharmacy and Strategies to over...
Barriers of patient counseling in a community pharmacy and Strategies to over...
 

Semelhante a Common Adverse Drug Reactions

Pharmacovigilance- an overview
Pharmacovigilance- an overviewPharmacovigilance- an overview
Pharmacovigilance- an overview
ClinosolIndia
 
Ashutosh pharmacovigilance
Ashutosh pharmacovigilance Ashutosh pharmacovigilance
Ashutosh pharmacovigilance
ASHUTOSH MISHRA
 
Management of patient with neurologic disorders
Management of patient with neurologic disordersManagement of patient with neurologic disorders
Management of patient with neurologic disorders
Sheila May Alipio
 

Semelhante a Common Adverse Drug Reactions (20)

Detection, reporting and monitoring of ad rs final ppt
Detection, reporting and monitoring of ad rs final pptDetection, reporting and monitoring of ad rs final ppt
Detection, reporting and monitoring of ad rs final ppt
 
MHRA Yellow Card Scheme
MHRA Yellow Card SchemeMHRA Yellow Card Scheme
MHRA Yellow Card Scheme
 
adverse drug reactions and adrs monitoring
adverse drug reactions and adrs monitoringadverse drug reactions and adrs monitoring
adverse drug reactions and adrs monitoring
 
ADVERSE DRUG REACTIONS_LASUCOM LECTURE.ppt
ADVERSE DRUG REACTIONS_LASUCOM LECTURE.pptADVERSE DRUG REACTIONS_LASUCOM LECTURE.ppt
ADVERSE DRUG REACTIONS_LASUCOM LECTURE.ppt
 
Pharmacovigilance- an overview
Pharmacovigilance- an overviewPharmacovigilance- an overview
Pharmacovigilance- an overview
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
ADR SEMINAR.pptx
ADR SEMINAR.pptxADR SEMINAR.pptx
ADR SEMINAR.pptx
 
High alert medication
High alert medicationHigh alert medication
High alert medication
 
Adverse Drug Reaction (ADR) Pharmacovigilance
Adverse Drug Reaction (ADR) Pharmacovigilance Adverse Drug Reaction (ADR) Pharmacovigilance
Adverse Drug Reaction (ADR) Pharmacovigilance
 
ADR-RDP-2023.pdf
ADR-RDP-2023.pdfADR-RDP-2023.pdf
ADR-RDP-2023.pdf
 
Ashutosh pharmacovigilance
Ashutosh pharmacovigilance Ashutosh pharmacovigilance
Ashutosh pharmacovigilance
 
Adverse drug reactions
Adverse drug reactionsAdverse drug reactions
Adverse drug reactions
 
Pharmacovigilance
Pharmacovigilance Pharmacovigilance
Pharmacovigilance
 
Teratology dr. hussein abass 2006
Teratology     dr. hussein abass    2006Teratology     dr. hussein abass    2006
Teratology dr. hussein abass 2006
 
Medical emergencies in dentisry
Medical emergencies in dentisryMedical emergencies in dentisry
Medical emergencies in dentisry
 
Chemotherapy induced disorders by sara ahmed yadallah
Chemotherapy induced disorders by sara ahmed yadallahChemotherapy induced disorders by sara ahmed yadallah
Chemotherapy induced disorders by sara ahmed yadallah
 
Venous Thromboembolism
Venous ThromboembolismVenous Thromboembolism
Venous Thromboembolism
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Management of patient with neurologic disorders
Management of patient with neurologic disordersManagement of patient with neurologic disorders
Management of patient with neurologic disorders
 
Humira
HumiraHumira
Humira
 

Mais de Dr Htet

Mais de Dr Htet (19)

Drug therapy of depression
Drug therapy of depression Drug therapy of depression
Drug therapy of depression
 
Whys & Wherefores in clinical pharmacology (1)
Whys & Wherefores in clinical pharmacology (1)Whys & Wherefores in clinical pharmacology (1)
Whys & Wherefores in clinical pharmacology (1)
 
Calcium Channel Blockers
Calcium Channel Blockers Calcium Channel Blockers
Calcium Channel Blockers
 
Calcium Channel Blockers
Calcium Channel Blockers Calcium Channel Blockers
Calcium Channel Blockers
 
Drug therapy of congestive heart failure
Drug therapy of congestive heart failureDrug therapy of congestive heart failure
Drug therapy of congestive heart failure
 
Pharmacology of Organic Nitrates
Pharmacology of Organic Nitrates Pharmacology of Organic Nitrates
Pharmacology of Organic Nitrates
 
Drugs acting on Renin Angiotensin Aldosterone system
Drugs acting on Renin Angiotensin Aldosterone system Drugs acting on Renin Angiotensin Aldosterone system
Drugs acting on Renin Angiotensin Aldosterone system
 
Drug therapy of hypercholesterolaemia
Drug therapy of hypercholesterolaemia Drug therapy of hypercholesterolaemia
Drug therapy of hypercholesterolaemia
 
Antiviral Agents
Antiviral Agents Antiviral Agents
Antiviral Agents
 
Drug Therapy of Depression
Drug Therapy of Depression Drug Therapy of Depression
Drug Therapy of Depression
 
Pharmacokinetic changes of drugs in hepatic diseases
Pharmacokinetic changes of drugs in hepatic diseasesPharmacokinetic changes of drugs in hepatic diseases
Pharmacokinetic changes of drugs in hepatic diseases
 
Pharmacokinetic changes in renal impairment and dosage considerations
Pharmacokinetic changes in renal impairment and dosage considerationsPharmacokinetic changes in renal impairment and dosage considerations
Pharmacokinetic changes in renal impairment and dosage considerations
 
Pharmacokinetics of oral cavity
Pharmacokinetics of oral cavityPharmacokinetics of oral cavity
Pharmacokinetics of oral cavity
 
Introduction to Neuropharmacology
Introduction to Neuropharmacology Introduction to Neuropharmacology
Introduction to Neuropharmacology
 
Anticholinergics Drugs for Optometry
Anticholinergics Drugs for Optometry Anticholinergics Drugs for Optometry
Anticholinergics Drugs for Optometry
 
Cholinergic Drugs and Anticholinesterases in Optometry
Cholinergic Drugs and Anticholinesterases in Optometry Cholinergic Drugs and Anticholinesterases in Optometry
Cholinergic Drugs and Anticholinesterases in Optometry
 
Introduction to ANS Pharmacology
Introduction to ANS Pharmacology Introduction to ANS Pharmacology
Introduction to ANS Pharmacology
 
Medicines, Legislations and Optometrists
Medicines, Legislations and Optometrists Medicines, Legislations and Optometrists
Medicines, Legislations and Optometrists
 
Drugs and The Liver
Drugs and The Liver Drugs and The Liver
Drugs and The Liver
 

Último

Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the HeartCardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
MedicoseAcademics
 
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
DR SETH JOTHAM
 

Último (20)

Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the HeartCardiac Impulse: Rhythmical Excitation and Conduction in the Heart
Cardiac Impulse: Rhythmical Excitation and Conduction in the Heart
 
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.GawadHemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
Hemodialysis: Chapter 1, Physiological Principles of Hemodialysis - Dr.Gawad
 
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.GawadHemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
Hemodialysis: Chapter 2, Extracorporeal Blood Circuit - Dr.Gawad
 
Tips and tricks to pass the cardiovascular station for PACES exam
Tips and tricks to pass the cardiovascular station for PACES examTips and tricks to pass the cardiovascular station for PACES exam
Tips and tricks to pass the cardiovascular station for PACES exam
 
DIGITAL RADIOGRAPHY-SABBU KHATOON .pptx
DIGITAL RADIOGRAPHY-SABBU KHATOON  .pptxDIGITAL RADIOGRAPHY-SABBU KHATOON  .pptx
DIGITAL RADIOGRAPHY-SABBU KHATOON .pptx
 
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best supplerCas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
Cas 28578-16-7 PMK ethyl glycidate ( new PMK powder) best suppler
 
Evidence-based practiceEBP) in physiotherapy
Evidence-based practiceEBP) in physiotherapyEvidence-based practiceEBP) in physiotherapy
Evidence-based practiceEBP) in physiotherapy
 
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
Vaccines: A Powerful and Cost-Effective Tool Protecting Americans Against Dis...
 
Cardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac PumpingCardiovascular Physiology - Regulation of Cardiac Pumping
Cardiovascular Physiology - Regulation of Cardiac Pumping
 
TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...
TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...
TEST BANK for The Nursing Assistant Acute, Subacute, and Long-Term Care, 6th ...
 
5Cladba ADBB 5cladba buy 6cl adbb powder 5cl ADBB precursor materials
5Cladba ADBB 5cladba buy 6cl adbb powder 5cl ADBB precursor materials5Cladba ADBB 5cladba buy 6cl adbb powder 5cl ADBB precursor materials
5Cladba ADBB 5cladba buy 6cl adbb powder 5cl ADBB precursor materials
 
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS by Dr M.KARTHIK EMMANUEL
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS  by Dr M.KARTHIK EMMANUELCONGENITAL HYPERTROPHIC PYLORIC STENOSIS  by Dr M.KARTHIK EMMANUEL
CONGENITAL HYPERTROPHIC PYLORIC STENOSIS by Dr M.KARTHIK EMMANUEL
 
Case presentation on Antibody screening- how to solve 3 cell and 11 cell panel?
Case presentation on Antibody screening- how to solve 3 cell and 11 cell panel?Case presentation on Antibody screening- how to solve 3 cell and 11 cell panel?
Case presentation on Antibody screening- how to solve 3 cell and 11 cell panel?
 
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptxIs Rheumatoid Arthritis a Metabolic Disorder.pptx
Is Rheumatoid Arthritis a Metabolic Disorder.pptx
 
Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.Muscle Energy Technique (MET) with variant and techniques.
Muscle Energy Technique (MET) with variant and techniques.
 
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
THORACOTOMY . SURGICAL PERSPECTIVES VOL 1
 
In-service education (Nursing Mangement)
In-service education (Nursing Mangement)In-service education (Nursing Mangement)
In-service education (Nursing Mangement)
 
Overview on the Automatic pill identifier
Overview on the Automatic pill identifierOverview on the Automatic pill identifier
Overview on the Automatic pill identifier
 
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالةGallbladder Double-Diverticular: A Case Report  المرارة مزدوجة التج: تقرير حالة
Gallbladder Double-Diverticular: A Case Report المرارة مزدوجة التج: تقرير حالة
 
Introducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European UnionIntroducing VarSeq Dx as a Medical Device in the European Union
Introducing VarSeq Dx as a Medical Device in the European Union
 

Common Adverse Drug Reactions

  • 1. Dr Htet Htet MBBS, MMedSc (Pharmacology) Lecturer Clinical Pharmacology
  • 3. History • Thalidomide - 1957 - in West Germany • The German drug company “Grünenthal” developed and sold the drug. • Primarily prescribed as a sedative or hypnotic, to cure “anxiety, insomnia, gastritis, and tension". • Afterwards it was used against nausea and to alleviate morning sickness in pregnant women.
  • 4. • became an over the counter drug in Germany around 1960, and • could be bought without a prescription. • Shortly after the drug was sold, in Germany, between 5,000 and 7,000 infants were born with malformation of the limbs (phocomelia). Only 40% of these children survived.
  • 5. Time to Investigate • statistic - “50 % of the mothers with deformed children had taken thalidomide during the first trimester of pregnancy.” • Throughout Europe, Australia, Canada and some part of America - cases were reported of infants with phocomelia; only 50% of them survived. • Those subjected to thalidomide while in the womb experienced- limb deficiencies - long limbs either were not developed or presented as stumps. • Other effects - deformed eyes, hearts, alimentary, and urinary tracts, and blindness and deafness. • During that time period the use of medications during pregnancy was not strictly controlled, and drugs were not thoroughly tested for potential harm to the fetus.
  • 6. Time to withdrawn from market • Thalidomide was withdrawn from the market in 1961 • IT WAS A BIG LESSON FOR THE WHOLE WORLD CONCERNING WITH DRUG SAFETY AND REGULATION
  • 7.
  • 8.
  • 9.
  • 10.
  • 11. - An adverse drug reaction (ADR) is an expression that describes harm associated with the use of given medications at a normal dosage during normal use. - ADRs may occur following a single dose or prolonged administration of a drug or result from the combination of two or more drugs. - The meaning of this expression differs from the meaning of "side effect", as it might also imply that the effects can be beneficial.
  • 12.
  • 13. • Over 2 MILLION serious ADRs yearly • 100,000 DEATHS yearly • ADRs 4th leading cause of death ahead of pulmonary disease, diabetes, AIDS, pneumonia, accidents and automobile deaths • Ambulatory patients ADR rate—unknown • Nursing home patients ADR rate— 350,000 yearly Data from Institute of Medicine, National Academy Press, 2000 Lazarou J et al. JAMA 1998;279(15):1200–1205 Gurwitz JH et al. Am J Med 2000;109(2):87–94
  • 14.
  • 15. • Type A: – Augmented pharmacologic effects - dose dependent and predictable • Type B: – Bizarre effects (or idiosyncratic) - dose independent and unpredictable • Type C: Chronic effects (continuous) • Type D: Delayed effects • Type E: End-of-treatment effects • Types A and B were proposed in the 1970s,and the other types were proposed subsequently when the first two proved insufficient to classify ADRs.
  • 16. • 80% of ADR, • usually a consequence of the drug’s primary pharmacological effect (e.g. bleeding from warfarin)or • a low therapeutic index (e.g. nausea from digoxin), and • predictable • dose-related, usually mild, • But may be serious or even fatal (e.g. intracranial bleeding from warfarin). • usually due to inappropriate dosage, especially when drug elimination is impaired. • The term ‘side effects’ is often applied to minor type A reactions.
  • 17. • Bizarre effects (or idiosyncratic) • dose independent and • Unpredictable (not an extension pharmacological action of the drug) For example: • hepatotoxicity due to paracetamol • tinnitus induced by aspirin • ototoxicity with aminoglycosides of main
  • 18. • Results from Chronic or continuous use For example • Analgesic nephropathy • osteoporosis during continued high-dose glucocorticoid therapy • tardive dyskinesia during continuous use of antipsychotic drugs
  • 19. • Teratogenic Thalidomide - amelia or micromelia or phocomelia phenytoin -fetal hydantoin syndrome tetracyclines -teeth malformation and discoloration aspirin -early closure of ductus arteriosus carbamazepine -cleft lip and palate, microcephaly wafarin - saddle nose sodium valproate - spina bifida DES - vaginal clear cell adenocarcinoma
  • 20. • Rebound adrenal insufficiency • Withdrawal syndrome (tachycardia on abrupt discontinuation of β-adrenoceptor blockade) • second malignancies following successful chemotherapy.
  • 21. a. Adverse effects related to the pharmacological action of the drug main a. Adverse effects unrelated to the main pharmacological action of the drug
  • 22.
  • 23. • predictable, • at least this action is well understood. • They are sometimes referred to as type A ('augmented‘)
  • 24. Examples: • postural hypotension occurs with α1-adrenoceptor antagonists, • bleeding with anticoagulants, • sedation with anxiolytics • intracerebral bleeding caused by anticoagulants, • hypoglycaemic coma from insulin • drug dependence produced by opioid analgesics
  • 25.
  • 26. Examples • paracetamol hepatotoxicity • aspirin-induced tinnitus when susceptibility is increased • eg. during pregnancy Or if the patient has some predisposing conditions, • glucose 6-phosphate dehydrogenase deficiency • mutation in the mitochondrial DNA that predisposes to aminoglycoside ototoxicity
  • 27. Unpredictable idiosyncratic reactions – drug-induced hepatic or renal necrosis, – bone marrow suppression, – carcinogenesis and – disordered fetal development. – aplastic anaemia from chloramphenicol – anaphylaxis in response to penicillin idiosyncratic reactions are termed type B ('bizarre') in the Rawlins & Thomson (1985) classification.
  • 28. • such reactions cannot be excluded by preapproval clinical trials (which might typically expose only a few thousand individuals to the drug), and • the association may come only after years of use, • so there is a need for continued monitoring by regulatory authorities after drugs have been licensed and marketed. • An example is the association between pulmonary hypertension and valvular heart disease with fenfluramine, an appetite suppressant that had been used for several years, and also with dexfenfluramine.
  • 29. Erythematous maculopapular eruption due to penicillin: rashes of this kind are by far the most common reactions to drugs. Vervloet D , and Durham S BMJ 1998;316:1511-1514 ©1998 by British Medical Journal Publishing Group
  • 30. Erythema multiforme due to sulphonamide treatment, showing characteristic target-like lesions. Vervloet D , and Durham S BMJ 1998;316:1511-1514 ©1998 by British Medical Journal Publishing Group
  • 31. Fixed drug eruption, so called because the lesion recurs at the same site after each administration—in this case, due to barbiturates. Vervloet D , and Durham S BMJ 1998;316:1511-1514 ©1998 by British Medical Journal Publishing Group
  • 32. Exfoliative dermatitis—a severe complication in this case due to co-trimoxazole. Vervloet D , and Durham S BMJ 1998;316:1511-1514 ©1998 by British Medical Journal Publishing Group
  • 33. Eiferman et al. Ciprofloxacin microprecipitates and macroprecipitates in the human corneal epithelium. J Cataract Refract Surg 2001; 27(10): 1701-2
  • 34. Brazier et al. Ecstasy related periodontitis and mucosal ulceration—a case report. Br Dent J 2003; 194(4): 197-9
  • 35.
  • 36.
  • 37.
  • 38.
  • 39.
  • 40.
  • 41. • toxicity testing in animals and humans are important for seeking approval to market a new drug. • Nevertheless, harmful effects are often encountered during therapeutic use, often the result of misprescribing, but also due to the emergence of toxic effects not detected in animals. • These harms are usually referred to as 'adverse drug reactions' (ADRs) and are of great concern to drug regulatory authorities, • For establishing the safety as well as the efficacy of drugs.
  • 42.
  • 43. 1. Listen to your patient (Patients may tell you about symptoms they have experienced since taking a new medicine and it is important to listen to the patient’s own concerns regarding their drug therapy.) 2. Alert by yourself (some adverse reactions may not be apparent to the patient, you will need to be alert to the possible occurrence of ADRs.)
  • 44. 3. Trust your own observations and initiative - vital in this respect, in linking a sign or symptom to either current or previous therapy. (Remember these can include overthe-counter (OTC) drugs and unlicensed herbal remedies).
  • 45. Other things to be alert for include: • Abnormal clinical measurements (e.g. temperature, pulse, blood pressure, blood glucose, body weight) while on drug therapy • Abnormal biochemical or haematological laboratory results while on drug therapy. For example, plasma drug concentrations or liver biopsy where drug-induced hepatitis is suspected
  • 46.
  • 47.
  • 48. • Introduced in 1964 after Thalidomide tragedy • Spontaneous reporting system • Early warning system • Over 600,000 confidential reports received in UK
  • 50. Where to report? • www.yellowcard.gov.uk (online completion) • http://yellowcard.mhra.gov.uk/ • Or by calling to 0808 100 3352 • Yellow cards can be available in BNF books ..
  • 51. When to report? • • • • • If you suspect ADR, Do not assume someone else will be reported. Only 2-4% of ADR are reported. Only 10% of serious ADR are reported. “No” You don’t need to be completely certain that what you have seen is ADR. ***
  • 52. How to get latest informations for yourself? • don’t miss for updates for yourself also. • DRUG SAFETY UPDATES!! • Published monthly • Register for updates .. • http://www.mrha.gov.uk/publications/safetyg uidance/DrugSafetyUpdate/index.htm
  • 53.
  • 54.
  • 55.
  • 56.
  • 57.
  • 58.
  • 59.
  • 60.
  • 61. • Vigabactrin – visual field defects • Cyproterone acetate – hepatotoxicity • Alendronate – severe oesophageal toxicity • sibutramine – (Meridia (sibutramine): – Market Withdrawal Due to Risk of Serious Cardiovascular Events) 2010-2011
  • 62.
  • 63. “All health care professionals have a responsibility to inform colleagues about clinically important drug reactions that they detect, even if a well recognized or causal link is uncertain”. Edwards IR and Aroson JK. Adverse Drug Reactions: Definitions, Diagnosis and Management. Lancet 2000; 356:
  • 65. • http://en.wikipedia.org/wiki/Thalidomide • http://www.who.int/bulletin/volumes/91/8/BLT12-111609-table-T1.html • http://www.fda.gov/Drugs/DevelopmentApprova lProcess/DevelopmentResources/DrugInteraction sLabeling/ucm114848.htm • http://www.mhra.gov.uk/Safetyinformation/How wemonitorthesafetyofproducts/Medicines/TheYe llowCardScheme/Informationforhealthcareprofes sionals/Adversedrugreactions/index.htm • http://www.docstoc.com/docs/57017777/TheYellow-Card-Scheme-Reporting • British National Formularly (61st Edition)